conferenceseries.com
1086th Conference

Scientific Program

8TH ASIAN BIOLOGICS AND BIOSIMILARS CONGRESS

AUGUST 10-12, 2017 BEIJING, CHINA



Hosting Organization: Conference Series LLC
One Commerce Center-1201, Orange St. #600, Wilmington, Zip-19899, Delaware, USA
Ph: +1-702-508-5200, Fax: +1-650-618-1417, Toll free: +1-800-216-6499
Email: asianbiosimilars@pharmaceuticalconferences.com

Day 1 August 10, 2017

09:00-09:30 **Registrations**

Hall

conferenceseries.com **09:30-09:40** **Opening Ceremony**

Keynote Forum

09:40-09:45 **Introduction**

09:45-10:35 **Title: FDA/EMA current thinking on totality of evidence for development of biosimilars**
Kamali Chance, Quintiles, IMS, USA

Group Photo

Networking & Refreshment Break: 10:35-10:55

10:55-11:45 **Title: Strategic partnership for China biologics**
Jianguo Yang, Abpro China, USA

11:45-12:35 **Title: Biosimilars: Accelerating early clinical development**
Raymond Huml, Quintiles IMS, USA

Lunch Break: 12:35-13:35

Sessions:
Challenges in Developing Biosimilars | Cost Analysis of Biosimilars | Emerging Trends in Biosimilars | Emerging Biosimilars in Therapeutics

Session Introduction

Session Chair: Darius Panaligan, Merck Group, Switzerland
Session Co-Chair: Hossein Pakdaman, Iranian Neurological Association, Iran

13:35-14:05 **Title: Challenges in assessing therapeutic equivalence of nano-similars**
Beat Fluehmann, Vifor Pharma Ltd, Switzerland

14:05-14:35 **Title: Challenges and opportunities in biosimilar commercialization**
Darius Panaligan, Merck Biosimilars, Switzerland

14:35-15:05 **Title: Convergence of regulatory expectations**
Robert Salcedo, Biosimilars Solutions and BioSciencesCorp, USA

Networking & Refreshment Break: 15:05-15:25

15:25-15:55 **Title: From neuromodulation to drug discovery and treatment**
Luis Ulloa, Rutgers University- New Jersey Medical School, USA

15:55-16:25 **Title: The role of regulatory policies in relation to the local biosimilars production**
Gustavo H Marin, UNLP-CONICET, Argentina

Day 1 Ends

Day 2 August 11, 2017

Hall

Keynote Forum

10:00-10:05 **Introduction**

10:05-10:55 **Title: Strategy for the global development of biosimilars: Putting it's all together**
Oxana Iliach, Quintiles IMS, Canada

Networking & Refreshment Break: 10:55-11:15

11:15-12:05 **Title: Clinical development of biosimilars for Western markets: Planning for success**
Charu Manaktala, Quintiles IMS, India

Lunch Break: 12:05-13:05

Sessions:
Globalization of Biosimilars | Biosimilars Market Challenges & Prospects | Pharmacovigilance of Biosimilars

Session Introduction

Session Chair: Robert Salcedo, Biosimilars Solutions and BioSciencesCorp, USA
Session Co-Chair: Hossein Pakdaman, Iranian Neurological Association, Iran

13:05-13:35 **Title: Science and commercial power, battle of the giants in biosimilars: 10 years perspective**
Richard Littlewood, Appliedstrategic, London, UK

13:35-14:05	**Title: Biosimilars in the UK's NHS: Attitudes, appetites and acceptance** **Divya Chadha Manek,** NHR, UK
14:05-14:35	**Title: Comparison of biosimilar registration guidelines between EU and USA** **Frank Cheng,** Alban Pharma, Hong Kong

Special Session

14:35-15:15	**Title: Biosimilars: Challenges in safety and risk management** **Asif Mahmood,** Pfizer, USA

Networking & Refreshment Break: 15:15-15:35

Poster Presentation @ 15:35-16:00

BS-01	**Title: Theodor Bilharz Research Institute therapeutic products and health tools** **Ismaeil Saad,** Theodor Bilharz Research Institute, Egypt
BS-02	**Title: Some considerations about biosimlar safety** **Samer M Al-Hulu,** Al-Qasim Green University, Iraq
BS-03	**Title: Biosimilars: Overview, evolution and regulations assessment systematic development, regulations and molecules approved in Australia, Brazil, Malaysia, Japan, Singapore and South Korea** **Tomas Gabriel BAS,** Coquimbo, Chile

Day 2 Ends

Day 3 August 12, 2017

Hall

Keynote Forum

10:00-10:05	**Introduction**
10:05-10:55	**Title: Biosimilars in treatment of multiple sclerosis** **Hossein Pakdaman,** Iranian Neurological Association, Iran

Networking & Refreshment Break: 10:55-11:15

Sessions:

Emerging Biosimilars in Therapeutics | Clinical Studies on Biosimilars

Session Introduction

11:15-11:45	**Title: Practical considerations in clinical strategy to support the development of biologics device combination products** **Zhaoyang Li,** Sanofi, USA
11:45-12:15	**Title: Patient involvement in research** **Divya Chadha Manek,** NHR, UK
12:15-12:45	**Title: GMP Complliance: how critical to your success of biological product to the market** **Frank Cheng,** Alban Pharma, Hong Kong

Lunch Break: 12:45-13:45

Video Presentation

Title: Expression of *shiga-like* toxin fused to vascular endothelial growth factor in *E.coli* for targeting angiogenesis

Osama O Ibrahim, Bioinnovation, USA

Networking and Closing Ceremony

